Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS: We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. The primary end point was the overall remission rate (the rate of complete remission or complete remission with incomplete hematologic recovery) within 3 months. RESULTS: For this planned analysis, 75 patients received an infusion of tisagenlecleucel and could be evaluated for efficacy. The overall remission rate within 3 months was 81%, with all patients who had a response to treatment found to be negative for minimal residual disease, as assessed by means of flow cytometry. The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months. The median duration of remission was not reached. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel occurred in 73% of patients. The cytokine release syndrome occurred in 77% of patients, 48% of whom received tocilizumab. Neurologic events occurred in 40% of patients and were managed with supportive care, and no cerebral edema was reported. CONCLUSIONS: In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“Any grade 3 or 4 adverse event 19 (25) 33 (44) 8 (11) 4 (6)”
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 2×
“Increase in aspartate aminotransferase 5 (7) 2 (3) — —”
BackgroundSelf-citationGardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614 · cited 1×
“Decrease in neutrophil count 1 (1) 6 (8) 1 (1) 1 (1)”
Self-citationSabatino, M., Hu, J., Sommariva, M., Gautam, S., Fellowes, V., Hocker, J. D., Dougherty, S., Qin, H., Klebanoff, C. A., Fry, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683847 · Cited by 383
Cited by
Items 801–900 of 1,024
Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives
Sršen, L., Janžič, L., Ihan, A., & Kopitar, A. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1378944 · Cited by 80
Delivering living medicines with biomaterials
Harimoto, T., Jung, W., & Mooney, D. J. (2025) · Nature Reviews Materials · doi:10.1038/s41578-024-00766-y · Cited by 89
“For instance, CD19-targeted CAR T cells, such as Kymriah and Yescarta, can attack both malignant B cells and normal B cells, resulting in B cell aplasia 41–44 .”
Chou, C. K., & Turtle, C. J. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0602-5 · Cited by 76
Luo, H., Wang, N., Huang, L., Zhou, X., Jin, J., Li, C., Wang, D., Xu, B., Xu, J., Jiang, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0767-x · Cited by 78
Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells
Zolov, S. N., Rietberg, S. P., & Bonifant, C. L. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.07.005 · Cited by 74
Andersch, L., Radke, J., Klaus, A., Schwiebert, S., Winkler, A., Schumann, E., Grunewald, L., Zirngibl, F., Flemmig, C., Jensen, M. C., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6131-1 · Cited by 79
Schirrmacher, V. (2020) · Biomedicines · doi:10.3390/biomedicines8030061 · Cited by 79
“The US FDA and the European EMA recently approved two anti‐CD19 CAR‐T‐cell products, YESCARTA* (Axicabtagene Ciloleucel) and KYMRIAH* (Tisagenlecleucel), for the treatment of patients with CD19‐positive malignancies, such as refractory diffuse large B cell lymphoma (DLBCL) or relapsed or refractory B‐cell acute lympho…”
BackgroundCytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
Li, X., Daniyan, A. F., Lopez, A. V., Purdon, T. J., & Brentjens, R. J. (2020) · Leukemia · doi:10.1038/s41375-020-0874-1 · Cited by 76
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy
Feldmann, A., Hoffmann, A., Bergmann, R., Koristka, S., Berndt, N., Arndt, C., Loureiro, L. R., Kittel-Boselli, E., Mitwasi, N., Kegler, A., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1785608 · Cited by 77
Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
Matuszkiewicz‐Rowińska, J., & Małyszko, J. (2020) · Kidney & Blood Pressure Research · doi:10.1159/000509934 · Cited by 79
Driouk, L., Gicobi, J. K., Kamihara, Y., Rutherford, K. D., Dranoff, G., Ritz, J., & Baumeister, S. H. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580328 · Cited by 75
“9 39yo F, 16% BM blasts, FAB M6 (6;9) translocation 1.”
Cardiotoxicities of novel cancer immunotherapies
Stein-Merlob, A. F., Rothberg, M. V., Ribas, A., & Yang, E. H. (2021) · Heart · doi:10.1136/heartjnl-2020-318083 · Cited by 81
In Situ Programming of CAR T Cells
Parayath, N. N., & Stephan, M. T. (2021) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070620-033348 · Cited by 77
“2–5 × 106 transduced viable T cells per kilogram of body weight have been shown to be effective (95, 96).”
BackgroundZhao, Y., Liu, D., Sun, R., Zhang, J., Zhou, J., Wei, Z., Xiong, M., Cao, X., Lü, Y., Yang, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.605766 · Cited by 81
“BM+PB 80(76) 19(70) 61(78) PB 25(24) 8(30) 17(22) Neutrophil engraftment, days (range) 14(10-29) 14(11-20) 4(10-29) 0.”
Kverneland, A. H., Chamberlain, C. A., Borch, T. H., Nielsen, M., Mørk, S. K., Kjeldsen, J. W., Lorentzen, C. L., Jørgensen, L. P., Riis, L. B., Yde, C. W., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003499 · Cited by 77
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
Holland, E. M., Yates, B., Ling, A. L., Yuan, C. M., Wang, H., Stetler‐Stevenson, M., LaLoggia, M., Molina, J. C., Lichtenstein, D. A., Lee, D. W., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006035 · Cited by 77
Paasch, D., Meyer, J., Σταμοπούλου, Α., Lenz, D., Kuehle, J., Kloos, D., Buchegger, T., Holzinger, A., Falk, C. S., Kloth, C., et al. (2022) · Cells · doi:10.3390/cells11060994 · Cited by 76
Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia
Malczewska, M., Kośmider, K., Bednarz, K., Ostapińska, K., Lejman, M., & Zawitkowska, J. (2022) · Cancers · doi:10.3390/cancers14082021 · Cited by 93
“CD19 CAR-T-based drug tisagenlecleucel for the treatment of B-ALL in patients <26 years of age [85].”
BackgroundEfficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Chen, Q., Lu, L., & Ma, W. (2022) · Cancers · doi:10.3390/cancers14235983 · Cited by 78
Lakomy, T., Akhoundova, D., Nilius, H., Kronig, M.-N., Novak, U., Daskalakis, M., Bacher, U., & Pabst, T. (2023) · Biomolecules · doi:10.3390/biom13020382 · Cited by 76
Gagelmann, N., Ayuk, F. A., Atanackovic, D., & Kröger, N. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13380 · Cited by 80
Cellular therapy: Immune‐related complications
Oved, J. H., Barrett, D. M., & Teachey, D. T. (2019) · Immunological Reviews · doi:10.1111/imr.12768 · Cited by 75
Ramezankhani, R., Torabi, S., Minaei, N., Madani, H., Rezaeiani, S., Hassani, S., Gee, A. P., Dominici, M., Silva, D. N., Baharvand, H., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.547653 · Cited by 79
“The most common reported adverse events were fatigue, chills, and pyrexia (Maude et al., 2018).”
BackgroundFavalli, N., Bassi, G., Pellegrino, C. E., Millul, J., Luca, R. D., Cazzamalli, S., Yang, S., Trenner, A., Mozaffari, N. L., Myburgh, R., et al. (2021) · Nature Chemistry · doi:10.1038/s41557-021-00660-y · Cited by 73
Biological Therapies in the Treatment of Cancer—Update and New Directions
Papiez, M. A., & Krzyściak, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111694 · Cited by 81
“Several therapies have been developed for this leukemia: tisagenlecleucel has been approved for the treatment of pediatric patients with refractory B-ALL [235], then for patients up to 25 years of age with relapsed B-ALL and for adults with diffuse large B-cell lymphoma [236].”
BackgroundBrivio, E., Baruchel, A., Beishuizen, A., Bourquin, J., Brown, P. A., Cooper, T. M., Gore, L., Kolb, E. A., Locatelli, F., Maude, S. L., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.029 · Cited by 80
Self-citationŚliwa-Tytko, P., Kaczmarska, A., Lejman, M., & Zawitkowska, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105515 · Cited by 88
“Neurologic adverse effects were observed in 40–44% of children and young adults in studies using CAR constructs with a 4-1BB domain [78,79].”
BackgroundLi, Y., Ming, Y., Fu, R., Li, C., Wu, Y., Jiang, T., Li, Z., Ni, R., Li, L., Su, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.950923 · Cited by 86
“CAR-T therapies have currently been approved for the treatment of hematological malignancies including r/r B-lymphoblastic leukemia (r/r B-ALL), r/r B-cell non-Hodgkin lymphoma (NHL), and r/r multiple myeloma (r/r MM) (Maude et al., 2018; Abbasi et al., 2020; Abramson et al., 2020; Berdeja et al., 2021; Jain et al., 2…”
BackgroundCAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan, A. N., Asija, S., Pendhari, J., & Purwar, R. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14076 · Cited by 78
“4 .”
Emerging trends in clinical allogeneic CAR cell therapy
Li, Y.-R., Zhu, Y., Fang, Y., Lyu, Z., & Yang, L. (2025) · Med · doi:10.1016/j.medj.2025.100677 · Cited by 92
Cardiotoxicity of Immune Therapy
Ganatra, S., Parikh, R. B., & Neilan, T. G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.07.008 · Cited by 78
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Chiu, M. K.-L., Armstrong, E. J. L., Jennings, V., Foo, S., Crespo-Rodriguez, E., Bozhanova, G., Patin, E. C., McLaughlin, M., Mansfield, D., Baker, G., et al. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1729351 · Cited by 73
Alexander, M. D., Culos, K. A. A., Roddy, J. V. F., Shaw, J. R., Bachmeier, C. A., Shigle, T. L., & Mahmoudjafari, Z. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.01.014 · Cited by 76
Pediatric high‐grade glioma: moving toward subtype‐specific multimodal therapy
Chatwin, H. V., Cruz, J. C., & Green, A. L. (2021) · FEBS Journal · doi:10.1111/febs.15739 · Cited by 76
Jacoby, E., Ghorashian, S., Vormoor, B. J., Moerloose, B. D., Bodmer, N., Molostova, O., Yanir, A. D., Buechner, J., Elhasid, R., Bielorai, B., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01546-9 · Cited by 76
“Toxicity is significant, but for recipients of 4-1BB containing CAR T-cell products the incidences of severe CRS and severe ICANS were lower than in the pivotal studies for tisagenlecleucel [11], likely due to a lower disease burden prior to LD.”
BackgroundResultInfluentialSelf-citationAdvancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL
Pieters, R., Mullighan, C. G., & Hunger, S. P. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01286 · Cited by 76
Ouyang, W., Jin, S., Xu, N., Liu, W.-Y., Zhao, H. Q., Zhang, L., Kang, L., Tao, Y., Liu, Y., Wang, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008429 · Cited by 74
Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy
Liu, Y., Zang, X.-Y., Wang, J., Huang, S., Jiang, X., & Zhang, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109437 · Cited by 111
Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy
Zebley, C. C., Gottschalk, S., & Youngblood, B. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.008 · Cited by 69
“With the use of tisagenlecleucel, the rate of event-free survival was 50% and OS was 76% at 12 months post treatment, indicating that while CAR T-cell therapy is promising, further improvements are necessary to increase patient survival [12].”
MethodThe Chimeric Antigen Receptor Detection Toolkit
Hu, Y., & Huang, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01770 · Cited by 77
“Although CAR-T cell therapy’s preliminary clinical success in B cell cancers warrants optimism, there are several challenges in the CAR-T field that need to be addressed: (1) CAR-T cell therapy does not work on solid tumors; (2) clinical non-response/relapse mechanisms in B cell cancers need elucidation; (3) the in vi…”
BackgroundResultInfluentialMicrobiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy
Longhi, G., van Sinderen, D., Ventura, M., & Turroni, F. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.575072 · Cited by 71
Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
Neureiter, D., Stintzing, S., Kiesslich, T., & Ocker, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i25.3136 · Cited by 76
Heng, G., Jia, J., Li, S., Fu, G., Wang, M., Qin, D., Li, Y., Li, P., Tian, X., Zhang, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1339 · Cited by 77
“One of the causes of relapse is CD19-negative B-ALL progression (6); Maude and colleagues (1, 2) and Lee and colleagues (4) report that this was the case in approximately 10%–30% of relapsed patients.”
BackgroundSelf-citationGudiol, C., Lewis, R. E., Strati, P., & Kontoyiannis, D. P. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30376-8 · Cited by 72
Eckert, C., Parker, C. A., Moorman, A. V., Irving, J. A. E., Kirschner‐Schwabe, R., Groeneveld‐Krentz, S., Révész, T., Hoogerbrugge, P. M., Hancock, J. P., Sutton, R., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.034 · Cited by 70
“For patients with HR BCP-ALL, CD19- and CD22-targeted therapies with the CD19-directed bispecific T-cell engager blinatumomab, the CD22-directed toxin-conjugated monoclonal antibody inotuzumab ozogamicin [11e16] or chimeric antigen receptor T-cells (CAR-Ts) [17,18] offer superior remission rates, although the long-ter…”
BackgroundPortillo, A. L., Hogg, R., Poznanski, S. M., Rojas, E. A. P., Cashell, N. J., Hammill, J. A., Chew, M. V., Shenouda, M. M., Ritchie, T. M., Cao, Q., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102619 · Cited by 71
Lei, W., Xie, M., Jiang, Q., Xu, N., Li, P., Liang, A., Young, K. H., & Qian, W. (2021) · Cancers · doi:10.3390/cancers13153912 · Cited by 76
CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
Huang, J., Huang, X., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019115 · Cited by 78
Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions
Mishra, A., Maiti, R., Mohan, P., & Gupta, P. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14101 · Cited by 73
Modular pooled discovery of synthetic knockin sequences to program durable cell therapies
Blaeschke, F., Chen, Y. Y., Apathy, R., Dániel, B., Chen, A. Y., Chen, P. A., Sándor, K., Zhang, W., Li, Z., Mowery, C. T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.013 · Cited by 74
Duell, J., Leipold, A. M., Appenzeller, S., Fuhr, V., Rauert‐Wunderlich, H., Vià, M. D., Dietrich, O., Toussaint, C., Imdahl, F., Eisele, F., et al. (2023) · Blood · doi:10.1182/blood.2023021672 · Cited by 82
Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?
Mathias-Machado, M. C., de Jesus, V. H. F., Jacome, A. A. D. A., Donadio, M. D. S., Aruquipa, M. P. S., de Farias, J. P. F., Cunha, R., Silva, L. M. D., & Peixoto, R. D. (2024) · Cancers · doi:10.3390/cancers16030679 · Cited by 83
“Advanced cell therapy, utilizing genetically modified T cells to express a chimeric antigen receptor (CAR), is acknowledged as a crucial approach in cancer treatment [97–101].”
BackgroundRevitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 89
“399 Moreover, tumors undergo genetic changes that cause the loss of the target antigen, resulting in treatment resistance.”
InfluentialQuality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues
Li, Y., Huo, Y., Yu, L., & Wang, J. (2018) · Engineering · doi:10.1016/j.eng.2018.12.003 · Cited by 80
“On August 31, 2017, Novartis AG announced that tisagenlecleucel (previously known as CTL019, under the trade name Kymriah), a CAR-T cell product targeting CD19 that had been developed by the company, was approved by the US Food and Drug Administration (FDA) for the treatment of precursor B-cell acute lymphoblastic leu…”
BackgroundStein, A. S., Kantarjian, H. M., Gökbuget, N., Bargou, R. C., Litzow, M. R., Rambaldi, A., Ribera, J., Zhang, A., Zimmerman, Z. F., Zugmaier, G., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.04.010 · Cited by 70
“A subgroup analysis of patients with previous transplantation (n = 46) and without previous transplantation (n = 29) treated with the CAR T cell agent tisagenlecleucel showed a slightly higher rate of CR/CRh in the former group; the CR/CRh rate was 81% for the overall patient population [12].”
MethodCerrano, M., Ruella, M., Perales, M., Vitale, C., Faraci, D., Giaccone, L., Coscia, M., Maloy, M., Sánchez‐Escamilla, M., Elsabah, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00888 · Cited by 75
“The FDA granted the autologous CAR T-cell therapy tisagenlecleucel (CTL019 or tisa-cel, KYMRIAH R©, jointly developed by the UPenn and Novartis) breakthrough therapy designation for pediatric and young adult R/R B-ALL in July 2014.”
BackgroundInfluentialManipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy
Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69
Guha, A., Addison, D., Jain, P., Gutierrez, J. M., Ghosh, A. K., Roddie, C., Lima, M. J. G. D., Al-Kindi, S. G., & Oliveira, G. H. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.08.036 · Cited by 71
Roth, T. L., & Marson, A. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032626 · Cited by 79
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia
Maciocia, P. M., Wawrzyniecka, P. A., Maciocia, N., Burley, A., Karpanasamy, T., Devereaux, S., Hoekx, M., O’Connor, D., León, T. E., Rapoz-D’Silva, T., et al. (2022) · Blood · doi:10.1182/blood.2021013648 · Cited by 70
“Perhaps the most promising advance in r/r B-ALL is CAR-T cells, which lead to high rates of deep and sustained remissions, even in advanced and refractory disease 15,16 .”
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Heard, A. D., Landmann, J. H., Hansen, A. R., Papadopolou, A., Hsu, Y.-S., Selli, M. E., Warrington, J. M., Lattin, J., Chang, J., Ha, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31035-7 · Cited by 71
“…with chimeric antigen receptors (CARs) targeting the transmembrane protein CD19 have varied success in the treatment of B cell cancers. pediatric Response rates in patients with acute lymphoblastic leukemia (ALL) are high, with >85% achieving complete remission within 1 month of treatment 1,2 .”
Ghorashian, S., Jacoby, E., Moerloose, B. D., Rives, S., Bonney, D. K., Shenton, G., Bader, P., Bodmer, N., Quintana, Á. M., Herrero, B., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00225-3 · Cited by 76
Self-citationSynapse-tuned CARs enhance immune cell anti-tumor activity
Chockley, P. J., Ibañez-Vega, J., Krenciute, G., Talbot, L. J., & Gottschalk, S. M. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01650-2 · Cited by 69
“Despite considerable advances in chimeric antigen receptor (CAR)-based therapeutics, efficacy against solid tumors has eluded the most cutting-edge designs 1–3 .”
BackgroundPérez, C. A., Carmona-Luque, M. D., Benabdellah, K., & Herrera, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1165870 · Cited by 72
“Characterization of CD19 status revealed one patient having CD19-positive recurrence, 15 CD19-negative relapses and six with CD19 relapse unknown (5).”
BackgroundMethodBuilding a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Maia, A., Tarannum, M., Lérias, J. R., Piccinelli, S., Borrego, L. M., Maeurer, M. J., Romee, R., & Castillo-Martín, M. (2024) · Cells · doi:10.3390/cells13050451 · Cited by 74
“NK cells constitute approximately 5 to 10% of total lymphocytes in PB, exhibiting a mature phenotype with high cytotoxicity against tumors (Figure 3A) [1].”
BackgroundInfluentialAffinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects
Wang, Y., Buck, A., Piel, B. P., Zerefa, L., Murugan, N., Coherd, C. D., Miklosi, A. G., Johal, H., Bastos, R. N., Huang, K., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01952-w · Cited by 75
Greco, R., Ruggeri, A., McLornan, D. P., Snowden, J. A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Hazenberg, M. D., Kałwak, K., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02701-3 · Cited by 78
“In addition, anti-CD19 CAR-T cell therapy was approved for patients up to 25 years of age based on the ELIANA study [59], and for adult ALL based on the ZUMA-3 trial [60] and FELIX trial [61].”
Bispecific antibodies in haematological malignancies
Viardot, A., & Bargou, R. C. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.002 · Cited by 72
Will CAR T cell therapy have a role in AML? Promises and pitfalls
Cummins, K. D., & Gill, S. I. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.08.008 · Cited by 73
Nguyen, T., & Barr, F. G. (2018) · Molecules · doi:10.3390/molecules23112798 · Cited by 74
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 77
Springuel, L., Lonez, C., Alexandre, B., Cutsem, E. V., Machiels, J., den Eynde, M. V., Prenen, H., Hendlisz, A., Shaza, L., Carrasco, J., et al. (2019) · BioDrugs · doi:10.1007/s40259-019-00368-z · Cited by 72
IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly
Vairy, S., & Tran, T. H. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100677 · Cited by 75
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
Qin, L., Zhao, R., Chen, D., Wei, X., Wu, Q., Long, Y., Jiang, Z., Li, Y., Wu, H., Zhang, X., et al. (2020) · Biomarker Research · doi:10.1186/s40364-020-00198-0 · Cited by 70
“Two CAR-T cell products have been approved by the FDA to treat B-cell leukemia and lymphoma[3-6].”
BackgroundNK Cell-Based Immunotherapy for Hematological Malignancies
Sivori, S., Meazza, R., Quintarelli, C., Carlomagno, S., Chiesa, M. D., Falco, M., Moretta, L., Locatelli, F., & Pende, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101702 · Cited by 69
Pearson, A. D. J., Rössig, C., Lesa, G. M., Diede, S. J., Weiner, S. L., Anderson, J., Gray, J. C., Geoerger, B., Minard‐Colin, V., Marshall, L. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.12.029 · Cited by 73
“In principle, antigen-specific T cells can be activated in vivo by bispecific T cell engagers [79] or generated by CAR T cells [80 e 83] and TCR gene-modified T cells [84].”
BackgroundSong, W., & Zhang, M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108382 · Cited by 75
Natural Born Killers: NK Cells in Cancer Therapy
Franks, S. E., Wolfson, B., & Hodge, J. W. (2020) · Cancers · doi:10.3390/cancers12082131 · Cited by 75
“Two CAR-T therapies have been granted FDA approval as of this writing: tisagenlecleucel in relapsed/refractory B cell precursor acute lymphoblastic leukemia (ALL) [2], and axicabtagene ciloleucel in relapsed/refractory diffuse large B cell lymphoma [3], both specific for the B cell antigen CD19.”
BackgroundToward Better Understanding and Management of CAR-T Cell–Associated Toxicity
Schmidts, A., Wehrli, M., & Maus, M. V. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-061119-015600 · Cited by 72
Kimmel, G. J., Locke, F. L., & Altrock, P. M. (2021) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2021.0229 · Cited by 80
“Recent works used an empirical time-dependent modelling approach and compartment modelling [6] to describe the complicated temporal kinetics of the CAR T cell drug tisagenlecleucel [10].”
MethodSummers, C. N., Wu, Q. V., Annesley, C., Bleakley, M., Dahlberg, A. E., Narayanaswamy, P., Huang, W., Voutsinas, J. M., Brand, A., Leisenring, W. M., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.10.003 · Cited by 83
Leclercq-Cohen, G., Steinhoff, N., Haegel, H., Marco, D. D., Bacac, M., & Klein, C. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2083479 · Cited by 72
“Both T cell engagers and CAR-T cells are showing remarkable clinical efficacy, particularly to cure hematological tumors, opening an avenue for approval of other T cell engaging therapies.(17,18) Consequently, various CAR-T cell products and T cell engagers against a wide spectrum of solid tumors and hematological tum…”
BackgroundGenome-edited allogeneic donor “universal” chimeric antigen receptor T cells
Qasim, W. (2022) · Blood · doi:10.1182/blood.2022016204 · Cited by 73
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Qu, C., Zhang, H., Cao, H., Tang, L., Mo, H., Liu, F., Zhang, L., Yi, Z., Long, L., Yan, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01669-8 · Cited by 75
Uribe‐Herranz, M., Beghi, S., Ruella, M., Parvathaneni, K., Salaris, S., Κωστόπουλος, Ν., George, S. S., Pierini, S., Krimitza, E., Costabile, F., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.012 · Cited by 72
Self-citationCD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
Acharya, S., Başar, R., Daher, M., Rafei, H., Li, P., Uprety, N., Ensley, E. L., Shanley, M., Kumar, B., Banerjee, P. P., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0096 · Cited by 77
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Koirala, M., & DiPaola, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081801 · Cited by 75
“Bispecific antibodies are designed to engage two different targets simultaneously; for example, blinatumomab brings T cells into close proximity with cancer cells, enhancing the immune response [134].”
BackgroundCRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy
Salas-McKee, J., Kong, W., Gladney, W. L., Jadlowsky, J. K., Plesa, G., Suhoski, M. M., & Fraietta, J. A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571893 · Cited by 73
A brief history of CAR-T cells: from laboratory to the bedside
Styczyński, J. (2020) · Acta Haematologica Polonica · doi:10.2478/ahp-2020-0002 · Cited by 78
Rochigneux, P., Chanez, B., de Rauglaudre, B., Mitry, E., Chabannon, C., & Gilabert, M. (2021) · Cancers · doi:10.3390/cancers13020271 · Cited by 70
Levine, J. E., Grupp, S. A., Pulsipher, M. A., Dietz, A. C., Rives, S., Myers, G. D., August, K. J., Verneris, M. R., Buechner, J., Laetsch, T. W., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002287 · Cited by 74
Self-citationPharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines
Mehta, N. K., Pradhan, R. V., Soleimany, A. P., Moynihan, K. D., Rothschilds, A. M., Momin, N., Rakhra, K., Mata-Fink, J., Bhatia, S. N., Wittrup, K. D., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0563-4 · Cited by 66
Neurotoxicity—CAR T-cell therapy: what the neurologist needs to know
Neill, L., Rees, J. H., & Roddie, C. (2020) · Practical Neurology · doi:10.1136/practneurol-2020-002550 · Cited by 69
CARTmath—A Mathematical Model of CAR-T Immunotherapy in Preclinical Studies of Hematological Cancers
Barros, L. R. C., Paixão, E. A., Valli, A. M. P., Naozuka, G. T., Fassoni, A. C., & Almeida, R. C. (2021) · Cancers · doi:10.3390/cancers13122941 · Cited by 74
“The use of CAR-T cell immunotherapies is spreading across hematological cancers and has already turned into products of big pharma companies [55].”
BackgroundResultCurrent landscape of clinical development and approval of advanced therapies
Iglesias-López, C., Agustí, A., Vallano, A., & Obach, M. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.003 · Cited by 80
“In the case of Kymriah for relapsed or refractory B cell acute lymphoblastic leukemia (ALL), the single-arm design was planned to test for an improvement in overall remission rate relative to historical control rates from two previous studies performed for the same indication with other products (clofarabine and blina…”
ResultShao, M., Teng, X., Guo, X., Zhang, H., Huang, Y., Cui, J., Si, X., Ding, L., Wang, X., Li, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202103508 · Cited by 77
How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia
Kopmar, N. E., & Cassaday, R. D. (2022) · Blood · doi:10.1182/blood.2022017035 · Cited by 72
Velasco, R., Mussetti, A., Villagrán‐García, M., & Sureda, A. M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1144414 · Cited by 74
“Tisagenlecleucel (tisa-cel) Kymriah CD19 R/R B-ALL Children and young NCT02435849 ELIANA trial (4) 40% (13%)”
BackgroundInfluentialOverview of approved CAR-T products and utility in clinical practice
Bhaskar, S., Dholaria, B., Savani, B. N., Sengsayadeth, S. M., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.124277 · Cited by 84
Metadata
- Authors
- Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Oslo University Hospital (NO)
- Hospital Sant Joan de Déu Barcelona (ES)
- University of Minnesota (US)
- Children's Mercy Hospital (US)
- From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia (S.L.M., S.A.G.) — all in Philadelphia; the Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern...
- Royal Children's Hospital (AU)
- University of Southern California (US)
- ORCID
- Maude, Shannon L.
- Laetsch, Theodore W.
- Buechner, Jochen
- Rives, Susana
- Boyer, Michael
- Bittencourt, Henrique
- Bader, Peter
- Verneris, Michael R.
- Stefanski, Heather E.
- Qayed, Muna
- Hiramatsu, Hidefumi
- Davis, Kara L.
- Martin, Paul L.
- Nemecek, Eneida R.
- Yanik, Gregory A.
- Peters, Christina
- Boissel, Nicolas
- Mechinaud, Francoise
- Balduzzi, Adriana
- Krueger, Joerg
- June, Carl H.
- Levine, Bruce L.
- Zhang, Yiyun
- Lebwohl, David
- Pulsipher, Michael A.
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 439-448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5996391
- OpenAlex
- W2787301955
- Cited by
- 5,735
- References
- 24
- Citations by year
- 2026: 573 · 2025: 671 · 2024: 734 · 2023: 730 · 2022: 784 · 2021: 788 · 2020: 706 · 2019: 496 · 2018: 242
- FWCI
- 207.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tisagenlecleucel, CAR T-cell therapy, anti-CD19, B-cell acute lymphoblastic leukemia, relapsed/refractory leukemia, pediatric and young adult patients, complete remission, minimal residual disease, event-free survival, overall survival, cytokine release syndrome, neurological adverse events, CAR T cell persistence, tocilizumab, treatment toxicity
- MeSH terms
- Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Female, Humans, Infusions, Intravenous, Male, Receptors, Antigen, T-Cell, Remission Induction, Survival Analysis, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.